...
首页> 外文期刊>Journal of nephrology. >Comparison of pulse and oral steroid in childhood membranoproliferative glomerulonephritis.
【24h】

Comparison of pulse and oral steroid in childhood membranoproliferative glomerulonephritis.

机译:儿童膜增生性肾小球肾炎的脉搏和口服类固醇比较。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: There has been no controlled study comparing efficacy of pulse versus oral steroid therapy in childhood membranoproliferative glomerulonephritis (MPGN). This study aimed to compare these therapies and renal outcome over a long-term period for MPGN. METHODS: Outcome measures in 11 patients with MPGN treated with pulse methylprednisolone (MP) were compared with 8 patients with MPGN treated with oral prednisolone (P). RESULTS: Nineteen children with idiopathic MPGN (mean age 9.75 years, range 3.7-14 years) were followed for a mean period of 68.21 months (range 4-124 months). Both treatment groups were similar in demographic, clinical, laboratory and histopathological characteristics on presentation. In the pulse MP group, only 1 patient out of 11 progressed to end-stage renal failure (ESRF), compared with 4 patients out of 8 in the oral P group (p=0.041). For long-term renal survival, those patients with more than 8 years of follow-up were further evaluated. Twelve patients had completed 8 years of follow-up; in the pulse MP group, 1 of 7 patients, compared with 4 of 5 patients in the oral P group progressed to ESRF (p=0.039). Chronic damage in the presentation biopsy and lack of remission in patients with nephrotic syndrome (NS) were positively associated with adverse renal outcome (p=0.02, p=0.006, respectively). CONCLUSIONS: Pulse MP therapy may be superior to oral P therapy in children with MPGN in preserving renal function without any increase in steroid-related side effects. Chronic damage in the presentation biopsy and lack of remission of NS are adverse features.
机译:背景:目前尚无对照研究比较脉冲与口服类固醇激素治疗儿童膜性增生性肾小球肾炎(MPGN)的疗效。这项研究旨在比较MPGN长期使用的这些疗法和肾脏预后。方法:比较11例接受脉冲甲基强的松龙(MP)治疗的MPGN患者与8例口服强的松龙(P)治疗的MPGN患者的疗效。结果:19例特发性MPGN患儿(平均年龄9.75岁,范围3.7-14岁)接受了平均68.21个月(4-124个月)的随访。两种治疗组的人口统计学,临床,实验室和组织病理学特征均相似。在脉搏MP组中,只有11名患者中有1名患者发展为终末期肾衰竭(ESRF),而口服P组中8名患者中有4名患者发展为晚期肾衰竭(p = 0.041)。对于长期肾脏生存,对那些随访超过8年的患者进行了进一步评估。 12名患者完成了8年的随访;在脉搏MP组中,7例患者中有1例,而口服P组中5例患者中有4例进展为ESRF(p = 0.039)。肾活检综合征(NS)患者的表现活检中的慢性损伤和缺乏缓解与不良的肾脏结局呈正相关(分别为p = 0.02,p = 0.006)。结论:MPMP治疗MPGN的儿童在保持肾功能方面可能优于口服P疗法,而没有增加类固醇相关的副作用。表现活检中的慢性损伤和NS缺乏缓解是不利的特征。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号